Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus H umalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study
| Autor: | Christof M. Kazda, Jennifer Leohr, Thomas A. Hardy, Mary Anne Dellva, Christoph Kapitza, Mark Matzopoulos, Mei Teng Loh, Rong Liu, Shobha Reddy, Oliver Klein |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
Endocrinology Diabetes and Metabolism medicine.medical_treatment Pharmacology Endocrinology Pharmacokinetics Internal Medicine medicine Humans Hypoglycemic Agents Insulin Insulin lispro Dosing Cross-Over Studies Insulin Lispro business.industry Postprandial Period Crossover study Diabetes Mellitus Type 1 Glucose Postprandial Diabetes Mellitus Type 2 Tolerability Pharmacodynamics business medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 24:187-195 |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/dom.14561 |
| Popis: | AIMS To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes mellitus (T2D). MATERIALS AND METHODS This was a two-part, randomized, double-blind Phase 1b study. Part A used a six-period crossover design to assess PK and GD response to a solid mixed meal tolerance test (MMTT) following a single dose of URLi or Humalog administered 15 minutes before, immediately before, or 15 minutes after the start of the meal. Part B evaluated URLi or Humalog during 2 weeks of multiple daily dosing with a parallel design. The PK and GD were assessed following MMTTs at the beginning and end of the 2 weeks when insulins were administered immediately before the start of the meal. RESULTS URLi increased the insulin exposure within the first 30 minutes postdose by 2.2-fold and reduced the time to the early half-maximal drug concentration by 22.6% compared with Humalog. Overall, URLi resulted in better postprandial glucose lowering when dosed before, immediately before, or after a meal. In comparing the same meal-to-dose timing between the insulins, the postprandial glucose excursion over 5 hours was significantly reduced by 29%-105% for all three dose timings (-15, 0 and +15 minutes) with URLi. The PK and GD were sustained after daily subcutaneous dosing for 2 weeks in patients with T2D. URLi had more hypoglycaemic events during the MMTTs; few events occurred for both treatments during the 2 weeks of outpatient dosing. CONCLUSIONS URLi demonstrated accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings compared with Humalog and was well tolerated in patients with T2D. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text